Cargando…

Expression of CD22 in Triple-Negative Breast Cancer: A Novel Prognostic Biomarker and Potential Target for CAR Therapy

Triple-negative breast cancer (TNBC) accounts for 15–20% of all breast cancer cases. Due to the lack of expression of well-known molecular targets [estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2)], there is a need for more alternative treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zaib, Tahir, Cheng, Ke, Liu, Tingdang, Mei, Ruyi, Liu, Qin, Zhou, Xiaoling, He, Lifang, Rashid, Hibba, Xie, Qingdong, Khan, Hanif, Xu, Yien, Sun, Pingnan, Wu, Jundong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917013/ https://www.ncbi.nlm.nih.gov/pubmed/36768478 http://dx.doi.org/10.3390/ijms24032152

Ejemplares similares

CD22 is a potential target of CAR-NK cell therapy for esophageal squamous cell carcinoma
por: Liu, Tingdang, et al.
Publicado: (2023)

Recent Advances in Syndactyly: Basis, Current Status and Future Perspectives
por: Zaib, Tahir, et al.
Publicado: (2022)

Direct Differentiation of Human Embryonic Stem Cells to 3D Functional Hepatocyte-like Cells in Alginate Microencapsulation Sphere
por: Xie, Xiaoling, et al.
Publicado: (2022)

CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL
por: Fry, Terry J., et al.
Publicado: (2017)

Tremella fuciformis Crude Polysaccharides Attenuates Steatosis and Suppresses Inflammation in Diet-Induced NAFLD Mice
por: Khan, Tariq Jamal, et al.
Publicado: (2022)

Upregulation of CD22 by Chidamide promotes CAR T cells functionality
por: Yang, Xin, et al.
Publicado: (2021)

A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells
por: Fergusson, Nathan J., et al.
Publicado: (2023)

Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells
por: Dreyzin, Alexandra, et al.
Publicado: (2022)

Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy
por: Li, Wenjie, et al.
Publicado: (2023)

Efficacy and safety of CD22-specific and CD19/CD22-bispecific CAR-T cell therapy in patients with hematologic malignancies: A systematic review and meta-analysis
por: Li, Lili, et al.
Publicado: (2022)

Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma
por: Wu, Jiaying, et al.
Publicado: (2021)

Next Generation CD44v6-Specific CAR-NK Cells Effective against Triple Negative Breast Cancer
por: Raftery, Martin J., et al.
Publicado: (2023)

CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil
por: Nasiri, Fatemeh, et al.
Publicado: (2022)

CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report
por: Sun, Yao, et al.
Publicado: (2021)

A novel full-human CD22-CAR T cell therapy with potent activity against CD22(low) B-ALL
por: Tan, Yue, et al.
Publicado: (2021)

A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL
por: Zanetti, Samanta Romina, et al.
Publicado: (2022)

Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56
por: Zou, Fan, et al.
Publicado: (2019)

Engineered IL-7 Receptor Enhances the Therapeutic Effect of AXL-CAR-T Cells on Triple-Negative Breast Cancer
por: Zhao, Zhenhui, et al.
Publicado: (2020)

EGFR‐targeted CAR‐T cells are potent and specific in suppressing triple‐negative breast cancer both in vitro and in vivo
por: Xia, Lin, et al.
Publicado: (2020)

CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity
por: Jess, Jennifer, et al.
Publicado: (2023)

Immunotherapy of B cell lymphoma with CD22-redirected CAR NK-92 cells
por: Tian, Xiaopeng, et al.
Publicado: (2023)

Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy
por: Zhu, Haibo, et al.
Publicado: (2021)

Safety and efficacy of CD22 and CD19 CAR-T bridging auto-HSCT as consolidation therapy for AYA and adult B-ALL
por: Qiu, Yan, et al.
Publicado: (2023)

Intercellular Adhesion Molecule-1 as Target for CAR-T-Cell Therapy of Triple-Negative Breast Cancer
por: Wei, Heng, et al.
Publicado: (2020)

MRD-Negative Remission Induced in EP300-ZNF384 Positive B-ALL Patients by Tandem CD19/CD22 CAR T-Cell Therapy Bridging to Allogeneic Stem Cell Transplantation
por: Zhang, Xin-Yue, et al.
Publicado: (2021)

Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients
por: Qu, Changju, et al.
Publicado: (2022)

Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation
por: Jia, Hejin, et al.
Publicado: (2019)

S230: CD22 CAR T CELL THERAPY IS SAFE AND EFFECTIVE IN PATIENTS WITH LARGE B CELL LYMPHOMA WHO HAVE RELAPSED AFTER CD19 CAR T CELL THERAPY.
por: Frank, Matthew J., et al.
Publicado: (2023)

Failure of ALL recognition by CAR T cells: a review of CD 19-negative relapses after anti-CD 19 CAR-T treatment in B-ALL
por: Aparicio-Pérez, Clara, et al.
Publicado: (2023)

CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth
por: Zhou, Ru, et al.
Publicado: (2019)

Spatiotemporal PET Imaging Reveals Differences in CAR-T Tumor Retention in Triple-Negative Breast Cancer Models
por: Volpe, Alessia, et al.
Publicado: (2020)

Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer
por: Hu, Zhiwei
Publicado: (2020)

Long‐term outcomes of relapsed/refractory double‐hit lymphoma (r/r DHL) treated with CD19/22 CAR T‐cell cocktail therapy
por: Wei, Jia, et al.
Publicado: (2020)

Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
por: Dai, Hanren, et al.
Publicado: (2020)

Synthesis, Structural Characterization, and Water Vapor Sorption Behavior of Two Ligand Ratio-Dependent Supramolecular Networks, [Cd(2,2′-bpym)(1.5)(BDC)]·0.5(2,2′-bpym)·5H(2)O and [Cd(2,2′-bpym)(0.5)(BDC)(H(2)O)(3)]
por: Wang, Chih-Chieh, et al.
Publicado: (2022)

Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins
por: Blaeschke, Franziska, et al.
Publicado: (2021)

Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma
por: Roddie, Claire, et al.
Publicado: (2023)

Free interleukin-18 is elevated in CD22 CAR T-cell–associated hemophagocytic lymphohistiocytosis–like toxicities
por: Rocco, Joseph M., et al.
Publicado: (2023)

HER3 functions as an effective therapeutic target in triple negative breast cancer to potentiate the antitumor activity of gefitinib and paclitaxel
por: Lyu, Hui, et al.
Publicado: (2023)

Clinical Value of Preoperative Ultrasound Signs in Evaluating Axillary Lymph Node Status in Triple-Negative Breast Cancer
por: Wang, Jundong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ba64jr7e1cge97rcbdn85be4jv